Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $430K | $1.32M | $19.2M | $34.2M | $22.6M | $30.9M |
| Revenue growth | — | — | 206.7% | 1357.8% | 77.6% | -33.8% | 36.8% |
| Operating income | -$51.1M | -$68.5M | -$101M | -$117M | -$108M | -$103M | -$86.4M |
| Operating margin | — | -15937.4% | -7637.1% | -609.2% | -315.9% | -454.3% | -279.5% |
| Net income | -$51.1M | -$68.8M | -$101M | -$109M | -$98.4M | -$86.6M | -$74.3M |
| Net margin | — | -16000.0% | -7681.6% | -566.3% | -288.2% | -383.2% | -240.3% |
| EPS (diluted) | -$12.20 | -$6.23 | -$2.73 | -$2.62 | -$2.34 | -$1.58 | -$1.18 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$46.3M | -$31.3M | -$50.3M | $194M | -$118M | -$100M | -$86.1M |
| Capital expenditures | $968K | $16.2M | $3.31M | $1.21M | $1.22M | $906K | $50.0K |
| Free cash flow | -$47.3M | -$47.5M | -$53.6M | $192M | -$119M | -$101M | -$86.1M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $15.0M | $92.8M | $101M | $52.2M | $80.3M | $55.5M | $80.9M |
| Total assets | $22.3M | $256M | $520M | $405M | $286M | $284M | $198M |
| Total liabilities | $23.8M | $109M | $423M | $405M | $363M | $330M | $307M |
| Long-term debt | $11.0M | $19.7M | $0.00 | — | — | — | — |
| Shareholders' equity | -$88.0M | $146M | $96.9M | $112K | -$77.2M | -$45.5M | -$109M |
| Retained earnings | -$94.1M | -$163M | -$264M | -$373M | -$472M | -$558M | -$632M |
| Shares (wtd avg diluted) | 4.87M | 11.0M | 37.2M | 41.6M | 42.0M | 54.9M | 63.0M |
Every figure is extracted from Foghorn Therapeutics Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.